这项研究分析了他汀类药物在新的他汀类药物使用者中的使用情况,并评估了他汀类药物在韩国的市场动态。
本研究为回顾性队列研究。
他汀类药物的年度索赔数据来自国家健康保险服务-国家样本队列。
我们对韩国2003-2015年期间的新他汀类药物用户感兴趣。有关他汀类药物处方的信息,包括他汀类药物的强度以及新的和后续的他汀类药物进入市场,和开他汀类药物的医疗机构也被收集。在时间序列分析中,我们估计了市场引入仿制药的效果,特别适用于新处方的他汀类药物使用者。
这项由国家健康保险服务提供的样本队列的13年纵向研究发现,新的他汀类药物使用者的发病率从2003年的838.1/100000人增加到2015年的1626.9/100000人。大多数新用户都是在初级医疗机构开出的单一疗法开始的。然而,在韩国,新用户的他汀类药物市场非常活跃。首先,在研究期间,最常用的他汀类药物改变了数次.第二,中等强度他汀类药物的使用量从2003年的57%增加到2015年的92%.与这个结果一致,我们无法观察到在有选定疾病史的组中他汀类药物的处方存在实质性差异.最后,我们发现市场入侵或他汀类药物在新的他汀类药物使用者中转换,特别是在初级医疗机构。
与其他国家类似,在韩国,新的他汀类药物使用者的发病率有所增加.然而,与其他国家相比,韩国的他汀类药物市场相当活跃。有趣的是,在引入仿制药后,原件的折扣价立即扩大市场或替代市场,特别是在韩国的初级医疗机构。
This
study analysed utilisation of statins for new statin users and assessed market dynamics of statins in South Korea.
This
study is a retrospective cohort
study.
The yearly claims data for statins were retrieved from the National Health Insurance Service-National Sample Cohort.
We are interested in new statin users during 2003-2015 in Korea. Information on prescribed statins, including intensity of statins and entry of new and follow-on statins in the market, and healthcare institutions that prescribed the statins were also collected. In time series analysis, we estimated the effect of introduction of generics in the market, specifically for newly prescribed statin users.
This 13-year longitudinal
study of a sample cohort provided by the National Health Insurance Service found that the incidence of new statin user increase from 838.1/100 000 persons in 2003 to 1626.9/100 000 persons in 2015. Most new users were initiated on a monotherapy that was prescribed at primary healthcare institutions. However, the statin market for new users were quite dynamic in Korea. First, the most commonly prescribed statin changed several times during the
study period. Second, the use of moderate-intensity statins increased from 57% in 2003 to 92% in 2015. In line with this result, we could not observe substantial differences in prescription of statins in groups having selected diseases history. Lastly, we found market invasion or switch of statins among new statin users, specifically at primary healthcare institutions.
Similar to other countries, the incidence of new statin users has been increased in Korea. However, the statin market in Korea is quite dynamic compared with other countries. Interestingly, discounted price of originals after the introduction of generics immediately expand markets or substitute the market particularly in primary healthcare institutions in Korea.